[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595150":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":25,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":11,"id":66,"slug":11,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":11,"maxAge":11,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":79,"briefSummary":80,"conditions":81,"keywords":11,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Serum Progesterone Level on Day 3 After hCG Trigger",null,"3 Days After hCG Injection",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NA","SINGLE_GROUP","BASIC_SCIENCE",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20],{"label":21,"type":22,"description":11,"interventionNames":23},"1","EXPERIMENTAL",[24],"Drug: hCG",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","hCG","Subcutaneous injection of 250 µg of recombinant hCG (Ovitrelle®)",[21],[32],{"name":33,"affiliation":34,"role":35},"Noémie RANISAVLJEVIC, Investigator Coordinator","CHU de Montpellier","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Noémie RANISAVLJEVIC, Senior Lecturer - Hospital Pra","CONTACT","04 67 33 64 81","n-ranisavljevic@chu-montpellier.fr",{"name":43,"role":39,"phone":44,"phoneExt":11,"email":45},"Anne CADENE, Project manager","04.67.33.08.14","a-cadene@chu-montpellier.fr",[47],{"facility":48,"status":49,"city":50,"state":11,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Hôpital Arnaud de Villeneuve","RECRUITING","Montpellier","34000","France","FR",{"type":55,"coordinates":56},"Point",[57,58],3.87635,43.61093,{"lat":58,"lon":57},[61],{"name":62,"role":39,"phone":40,"phoneExt":63,"email":41},"Noémie RANISAVLJEVIC","+33",{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100595150",false,"NCT07028710","Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle","Evolution of Luteal Progesteronemia in a Modified Natural Cycle (Ovulation Triggered by hCG): Pilot Study","CineP4","Inclusion Criteria:\n\n* At least 1 follicle of 14 mm or more\n* Endometrium of 6 mm or more\n* Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng\u002FmL\n* For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care).\n\nExclusion Criteria:\n\n* Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period.\n* Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion.\n* Patient who has not given written consent to participate in the study.\n* Patient not fluent in French.\n* Patient under guardianship, curators or without social security coverage.\n* Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .",true,"FEMALE",{"count":76,"type":77},40,"ESTIMATED","INTERVENTIONAL",[14],"This pilot study evaluates how progesterone levels change after hCG-triggered ovulation in modified natural cycles. Forty women preparing for frozen embryo transfer will have blood tests over 6 days to monitor hormone levels. The goal is to understand whether hCG affects the timing of the luteal phase and embryo implantation.",[82],"Luteal Phase Insufficiency","2026-06-17",{"date":85,"type":86},"2026-06-22","ACTUAL",{"date":88,"type":86},"2026-01-12",{"date":90,"type":77},"2030-06-15",{"name":5,"class":6},1]